Emery Pharma and Marin Biologic Laboratories Announce Strategic Partnership to Advance Drug Development Capabilities
Alameda, CA, and Novato, CA – September 10, 2024 – Emery Pharma, a leader in bioanalytical chemistry, mass spectrometry, and CMC services, and Marin Biologic Laboratories, a premier provider of cell biology and biologics testing services, are excited to announce a strategic partnership. This collaboration will expand both companies’ capabilities to offer comprehensive solutions across the drug development lifecycle, from early-stage research to clinical manufacturing testing and regulatory compliance.
A Synergistic Approach to Drug Development
By combining the deep expertise of Emery Pharma in mass spectrometry, peptide mapping, and analytical chemistry with Marin Biologic Laboratories’ strengths in cell-based assays, immunoassays, gene therapy, and biologics clinical testing, this partnership creates an unparalleled offering for biotechnology, pharmaceutical, and medical device companies. Together, the companies will provide end-to-end services that streamline the complex process of developing both small and large molecules.
Dr. Ron Najafi, CEO of Emery Pharma, said, “This partnership represents a powerful alignment of our capabilities. Our advanced analytical chemistry and regulatory expertise, combined with Marin’s biologics and cell biology proficiency, will accelerate our clients’ journeys to market and offer a robust platform for innovation.”
Dr. Tania Weiss, CEO of Marin Biologic Laboratories, further added “We are excited to collaborate with Emery Pharma and utilize our unique skills and capabilities to provide exceptional service offerings to Clients. Our combined efforts will create a one-stop shop, whereby we will enhance efficiency and shorten timelines for Clients to bring innovative therapies to clinical testing and market expeditiously.”
Expanded Services for Clients
The collaboration will focus on delivering:
- Comprehensive CMC services: Streamlining drug manufacturing and control for biologics and small molecules, ensuring product quality and regulatory compliance.
- Mass spectrometry and peptide mapping: Offering in-depth molecular characterization using Emery Pharma’s innovative mass spectrometry technologies, including high-resolution Orbitrap and LC-MS systems.
- Cell-based assays and biologics testing: Supporting clients with pre-clinical and clinical assay development, drug release, stability studies and clinical PK assay through Marin Biologic Laboratories’ specialized services.
- Regulatory support: Providing critical FDA, GLP, and GMP consulting and ensuring seamless compliance across all phases of drug development.
This strategic collaboration between Emery Pharma and Marin Biologic Laboratories will drive innovation and create new opportunities for clients seeking comprehensive, reliable, and cost-effective solutions for drug development.
About Emery Pharma
Emery Pharma is a leading contract research organization (CRO) specializing in bioanalytical chemistry, mass spectrometry, and CMC services. Emery Pharma offers unparalleled speed and accuracy in method development, validation, and regulatory consulting, helping clients accelerate drug development and meet FDA requirements. Based in Alameda, CA, Emery Pharma supports clients globally across biotech, pharma, medical devices, and cleantech industries.
For more information, visit: http://www.emerypharma.com
Media Contact: Chris Purcell, Business Development Manager
Email: chris.purcell@emerypharma.com
Phone: (510) 899-8814
About Marin Biologic Laboratories
Marin Biologic Laboratories (MarinBio), a CRO with over 30 years of preclinical and clinical expertise, specializes in drug development and assay validation, including cell-based assays, lot release potency assays, stability testing, ELISA, PK/PD studies, immunogenicity, cellular immunoassays, flow cytometry, MLR, radioimmunoassay, molecular biology & microbiology, protein services, and PCR-qPCR. MarinBio provides comprehensive support throughout the drug development process, including IND/BLA applications, commercialization, and pharmacokinetics (PK). MarinBio’s cGMP/GLP services are designed to meet regulatory requirements for FDA and EU approvals, offering unmatched quality, prompt timelines, cost-effective solutions, and exceptional communication. With a robust Quality Management System in place, MarinBio ensures FDA-compliant analysis from validation to drug release and stability, working closely with the FDA and clients to achieve successful outcomes.
For more information, visit: http://www.marinbio.com
Media Contact: Tania Weiss, Ph.D. President & CEO
Email: t.weiss@marinbio.com
Phone: (415) 883-8000
